AU2003294446A1 - Regulation of stearoyl-coa desaturase to treat obesity - Google Patents

Regulation of stearoyl-coa desaturase to treat obesity

Info

Publication number
AU2003294446A1
AU2003294446A1 AU2003294446A AU2003294446A AU2003294446A1 AU 2003294446 A1 AU2003294446 A1 AU 2003294446A1 AU 2003294446 A AU2003294446 A AU 2003294446A AU 2003294446 A AU2003294446 A AU 2003294446A AU 2003294446 A1 AU2003294446 A1 AU 2003294446A1
Authority
AU
Australia
Prior art keywords
stearoyl
regulation
treat obesity
coa desaturase
desaturase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003294446A
Other versions
AU2003294446A8 (en
Inventor
Lizbeth Gallagher
Patricia Gallipoli
Stephen J. Gardell
Linda Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AU2003294446A8 publication Critical patent/AU2003294446A8/en
Publication of AU2003294446A1 publication Critical patent/AU2003294446A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
    • C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003294446A 2002-11-21 2003-11-21 Regulation of stearoyl-coa desaturase to treat obesity Abandoned AU2003294446A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42832502P 2002-11-21 2002-11-21
US60/428,325 2002-11-21
PCT/US2003/037354 WO2004047746A2 (en) 2002-11-21 2003-11-21 Regulation of stearoyl-coa desaturase to treat obesity

Publications (2)

Publication Number Publication Date
AU2003294446A8 AU2003294446A8 (en) 2004-06-18
AU2003294446A1 true AU2003294446A1 (en) 2004-06-18

Family

ID=32393382

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294446A Abandoned AU2003294446A1 (en) 2002-11-21 2003-11-21 Regulation of stearoyl-coa desaturase to treat obesity

Country Status (2)

Country Link
AU (1) AU2003294446A1 (en)
WO (1) WO2004047746A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043256A1 (en) 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
GT200600046A (en) 2005-02-09 2006-09-25 COMBINATION THERAPY
CA2793423C (en) 2010-06-11 2015-09-15 Avon Products, Inc. Use of eclipta prostrata and other ppar-gamma inhibitors in cosmetics and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5774699A (en) * 1998-08-14 2000-03-06 Johnson & Johnson Consumer Companies, Inc. Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
US20020041870A1 (en) * 2000-07-26 2002-04-11 Wu Linda H. Novel genes expressed in obese rat hypothalamus

Also Published As

Publication number Publication date
AU2003294446A8 (en) 2004-06-18
WO2004047746A3 (en) 2005-03-24
WO2004047746A2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
EP1534074A4 (en) Combination therapy for the treatment of obesity
AU2003278361A1 (en) Method of water treatment
AU2003217159A1 (en) Compositions and methods for the treatment of wastewater and other waste
AU2003271944A1 (en) Methods for making water treatment compositions and compositions thereof
AU2003225088A8 (en) Regulation of tnf-alpha
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
AU2003214211A1 (en) Enhancement of iron chelation therapy
AU2003210730A8 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
GB2408558B (en) Treatment of pipes
AU2003302724A1 (en) Methods of using vectors to treat metabolic disorders
AU2002359177A1 (en) Use of interleukin-6 for treatment of obesity
AU2003294446A1 (en) Regulation of stearoyl-coa desaturase to treat obesity
EP1575497A4 (en) Novel composition and methods for the treatment of psoriasis
AU2003268923A1 (en) Treatment of aml
AP2004003174A0 (en) Treatment of water
AU2003241346A1 (en) Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003283938A1 (en) Use of certain compounds in treatment of obesity
AU2002951622A0 (en) Improvements relating to treatment of waste materials
AU2003207315A1 (en) Treatment of muscle damage
AU2003263988A1 (en) Methods and compositions to treat conditions associated with neovascularization
AU2003255758A1 (en) Improvements relating to water treatment
IL164218A0 (en) Use of interleukin-19 to treat ovarian cancer
AU2003270615A8 (en) Treatment of steatosis using hyperthermia
AU2003258169A1 (en) Pharmacological treatment of psoriasis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase